GlobeNewsWire
14 Jun 2026, 07:15 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Legend Biotech's LB2501 achieved a 100% objective response rate and 83.3% complete response rate at the higher dose level (DL2) in patients with R/R B-cell non-Hodgkin lymphoma. — Exceptional efficacy rates in a heavily pretreated population provide strong clinical validation for a high-potential drug candidate.
+0.80LB2501 utilizes an 'in vivo' CAR-T approach, generating CAR-T cells directly within the patient without the need for lymphodepletion. — Moving from ex vivo to in vivo CAR-T would disrupt the current cell therapy model by significantly simplifying treatment and expanding patient access.
+0.70The therapy demonstrated a favorable safety profile with no dose-limiting toxicities, serious adverse events, ICANS, or deaths reported. — Absence of severe toxicity (like ICANS) is a critical derisking factor for cell therapies, making the drug more attractive to regulators and clinicians.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
The company announced successful first clinical proof-of-concept data for LB2501, showing a 100% objective response rate at the higher dose level and a favorable safety profile.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
